Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
2025 net product sales of $521 million 2026 expected global net product sales of $630 million to $650 million Volixibat VISTAS study in PSC topline data expected Q2 2026 LIVMARLI ® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026 Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026 Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY, Calif., February 25, 2026 BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. "2025 was a year of meaningful progress and execution for Mirum, setting the stage for a pivotal 2026," said Chris Peetz, Chief Executive Officer of Mirum. "With the recent addition of brelovitug in HDV, we now expect four potentially registrational readouts over the next 18 months, beginning with topline res
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta VirusBusiness Wire
- Mirum Pharmaceuticals (MIRM) was given a new $126.00 price target by Evercore Inc.MarketBeat
- A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $115.00 to $117.00. They now have a "buy" rating on the stock.MarketBeat
MIRM
Earnings
- 2/25/26 - Miss
MIRM
Sec Filings
- 2/25/26 - Form S-3ASR
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- MIRM's page on the SEC website